










































Minocycline,	 a	 second	 generation	 broad-spectrum	 antibiotic,	 has	 been	 frequently	 postulated	 to	 be	 a	
“microglia	 inhibitor”.	 A	 considerable	 number	 of	 publications	 have	 used	 minocycline	 as	 a	 tool	 and	
concluded,	 after	 achieving	 a	 pharmacological	 effect,	 that	 the	 effect	 must	 be	 due	 to	 “inhibition”	 of	
microglia.	It	is,	however,	unclear	how	this	“inhibition”	is	achieved	at	the	molecular	and	cellular	level.	Here	











preventing	 the	addition	of	new	amino	acids	 to	 the	nascent	peptide	chain	 (Chopra	and	Roberts	2001).	
Minocycline	has	a	long	serum	half	life	of	11-18	hours,	which	is	2-3	times	longer	than	the	typical	water-
soluble	 tetracyclines	 (Agwuh	 and	 MacGowan	 2006).	 Minocycline	 is	 the	 most	 lipid-soluble	 of	 the	
tetracycline	family,	affording	it	the	greatest	CNS	penetrance	in	the	group	(Brain-to-serum	ratio	in	dogs:	
minocycline	2.8;	doxycycline	1.3;	tetracycline	0.3)	(Barza	et	al.	1975).	While	this	is	an	obvious	advantage	















in	 PubMed.	 The	 reported	 mechanisms	 include	 inhibition	 of	 T-cell	 activation,	 inhibition	 of	 neutrophil	




1997;	Miyachi	 et	 al.	 1986;	 Ochsendorf	 2010;	 Pang	 et	 al.	 2012;	 Sadarangani	 et	 al.	 2015;	 Sapadin	 and	
Fleischmajer	2006;	Shapira	et	al.	1996;	Toussirot	et	al.	1997).	The	list	of	effects	is	far	from	complete	and	
one	has	to	keep	in	mind	that	not	all	properties	have	been	investigated	for	all	tetracyclines.	However,	there	
seems	 to	 be	 consensus	 that	 the	 second	 generation	 tetracyclines	 (e.g.	 doxycycline,	minocycline)	 have	
improved	anti-inflammatory	properties	(Garrido-Mesa	et	al.	2013;	Leite	et	al.	2011).	In	fact,	based	on	the	
intriguing	anti-inflammatory	properties	of	the	second	generation	tetracyclines,	efforts	are	underway	to	






target	 gene	 that	 is	under	 transcriptional	 control	of	 a	 tetracycline-responsive	promoter	element	 (TRE).	
These	 systems	 have	 found	wide	 adaption	 for	 the	 temporal	 regulation	 of	 gene	 expression	 or	 deletion	
(Mansuy	 and	 Bujard	 2000;	 Sakai	 2014;	 Zhu	 et	 al.	 2002b).	 While	 originally	 coined	 the	 “tetracycline	
regulated	expression	system”,	most	experiments	are	performed	with	doxycycline	as	the	Tet-On	system	
responds	poorly	 to	 tetracycline,	but	well	 to	doxycycline	(Baron	and	Bujard	2000).	 If	 these	systems	are	
used	to	investigate	an	animal	model	where	the	phenotype	is	associated	with	an	inflammatory	component,	




















for	minocycline	as	a	CNS	penetrant	anti-inflammatory	 these	data	are	not	 surprising.	However,	 several	






is	 being	 “inhibited”.	 Microglia	 “activation”?	 In	 turn,	 are	 only	 “activated”	 microglia	 effected	 my	
minocycline?	What	about	microglia	 “surveying”	 the	 tissue?	 It	 is	becoming	 clear	 that	microglia	exist	 in	
different	phenotypes	(Biber	et	al.	2014;	Hanisch	2013).	Consequently,	which	phenotype(s)	are	“inhibited”	




astrocytes,	 oligodendrocytes	 and	 neurons	 in	 vitro	 as	 well	 as	 in	 vivo.	 	 For	 example,	 minocycline	 (and	
doxycycline)	reduces	the	release	of	the	pro-inflammatory	cytokines	TNF-α,	 IL-6,	and	IL-8	from	cultured	
rhesus	monkey	 astrocytes	 (Bernardino	 et	 al.	 2009).	Minocycline	 reduced	 the	 number	 of	 hippocampal	
GFAP+	cells	in	LPS	challenged	mice	and	in	the	mutant	SOD1	model	of	amyotrophic	lateral	sclerosis	(Hou	
et	 al.	 2016;	 Keller	 et	 al.	 2011).	 Minocycline	 also	 protected	 oligodendrocytes	 and	 oligodendrocyte	
precursors	against	hypoxic	and	traumatic	 injury	 in	vitro	and	 in	vivo	 (Scheuer	et	al.	2015;	Schmitz	et	al.	
2012;	Stirling	et	al.	2004;	Yune	et	al.	2007).	There	is	a	plethora	of	reports	of	neuroprotection	and	direct	
effects	 on	 neurons	 by	 tetracyclines	 including	 minocycline	 (reviewed	 in	 (Domercq	 and	Matute	 2004).	
However,	the	effects	of	minocycline	are	not	always	positive.	Several	publications	report	neurotoxic	effects	
of	minocycline	(Arnoux	et	al.	2014;	Diguet	et	al.	2004a;	Diguet	et	al.	2004b;	Diguet	et	al.	2003;	Tsuji	et	al.	
2004;	Yang	et	al.	2003).	Of	course,	 in	 the	absence	of	proof	positive,	one	has	 to	acknowledge	 that	 the	
effects	on	astrocytes,	oligodendrocytes	and	neurons,	especially	 in	 vivo	 could	be	 indirect.	By	 the	 same	
token,	however,	 the	reported	effects	attributed	to	“microglia	 inhibition”	could	be	 indirect	as	well.	For	







therapy	 in	 indications	 ranging	 from	 atrial	 fibrillation,	 to	 Angelman	 Syndrome	 and	 schizophrenia	 (US-
National-Institutes-of-Health).	In	the	last	decade	minocycline	has	received	considerable	attention	for	CNS	














negative	 effect	 was	 later	 replicated	 in	 a	 mouse	 model	 of	 ALS	 where,	 in	 contrast	 to	 prior	 studies,	
minocycline		treatment	was	started	after	disease	onset	(Keller	et	al.	2011).	
Minocycline	is	not	a	selective	microglia	inhibitor	
The	 anti-inflammatory	 activity	 of	 minocycline	 (and	 other	 tetracyclines)	 is	 well	 documented	 and	
undisputed.	 However,	 whether	 this	 activity	 can	 be	 solely	 attributed	 to	 a	 “microglia	 inhibitory	 effect”	
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Tables:	
Table	1:	Anti-inflammatory	effects	of	selected	tetracyclines.	+	indicates	published	data	supporting	anti-
inflammatory	effect	of	a	given	drug.	CAVE:	Absence	of	proof	however,	is	not	proof	of	absence	of	the	
effect.		(Bernardino	et	al.	2009;	Bostanci	et	al.	2011;	Cazalis	et	al.	2009;	Celerier	et	al.	1996;	Eady	et	al.	
1993;	Garrido-Mesa	et	al.	2013;	Greenwald	et	al.	1992;	Jain	et	al.	2002;	Kloppenburg	et	al.	1996;	
Kloppenburg	et	al.	1995;	Koistinaho	et	al.	2004;	Milano	et	al.	1997;	Miyachi	et	al.	1986;	Ochsendorf	
2010;	Pang	et	al.	2012;	Sadarangani	et	al.	2015;	Sapadin	and	Fleischmajer	2006;	Shapira	et	al.	1996;	
Toussirot	et	al.	1997).	
	 	
	Figures	
Figure	1:	Chemical	structures	of	tetracycline,	doxycycline	and	minocycline.	
	
	
